The investigators will conduct a trial to evaluate if an online training and support platform can help adults living with type 1 diabetes (T1D) in their diabetes self-management. Investigators will compare a group that has access to the "Support" platform through their usual medical care to a group that accesses the platform independently. The first group will be recruited through four participating clinics in the province of Quebec (Canada). The second group will be composed of adults living with T1D across Canada. Participants will have access to the platform for 12 months and will be asked to complete online questionnaires at the beginning and after 6 and 12 months, and share their glucose reader data with the research team. A subgroup of participants as well as healthcare professionals from the four clinics will be invited to participate in an individual interview aiming to understand the barriers and facilitators of integration "Support" in clinical care.
Diagnosis of T1D (including LADA - latent autoimmune diabetes in adults)
Have access to Internet
Use of an active email address
Comprehension of English or French
None
Parallel
Support platform
BehavioralThe study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar. Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D.
Self-efficacy for diabetes management
Diabetes Self-Management Questionnaire-Revised (DSMQ-R; 27-items, score on 10)
Well-being
WHO-5 well-being index
Continuous Glucose Monitoring (CGM) - % Time in range
% Time in range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap.
Continuous Glucose Monitoring (CGM) - % Time above range
% Time above range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap.
Continuous Glucose Monitoring (CGM) - % Time below range
% Time below range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap.
Implementation question
Participants will be asked where they heard about the platform.
communication with health care team
Question about type (in-person, phone, video call or email) and frequency of communication with health care team
Engagement with Support platform (T1D patient) - time in minutes on platform
Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform
Engagement with Support platform (T1D patient) - total pages viewed
Engagement metrics will be extracted using Google analytics - total pages viewed from the platform
Click on the lead sponsor to view all of their trials.
McGill University
Lead sponsor
Institut de Recherches Cliniques de Montreal
Collaborator
Centre de Recheche du Centre Hospitalier Université Laval
Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborator
Centre de médecine métabolique de Lanaudière
Collaborator
